CAS: 13710-19-5; 2-((3-Chloro-2-Methylphenyl)Amino)Benzoic Acid

该化合物是一种属于胎儿类的非类状抗炎药物,化学配方C14H12ClNO2.它通过抑制环氧基酶(COX)酶,从而减少丙烯酸合成,表现出强效止痛,抗炎和抗热性特性.Tolfenamic酸由于其迅速吸收和有利的药理基因特征,在治疗偏头痛和其他急性疼痛症状方面特别有效.它选择性的COX-2在治疗剂量上的抑制会使胃肠侧效应与传统的非典ID相比最小化.此外,它表明临床使用毒性低且耐性强.由于能够调节Sp1等转录因素,该化合物还研究其潜在的抗癌特性.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号87-60-5 3-氯-2-甲基苯胺 | CAS号88-65-3 邻溴苯甲酸

合成工艺路线路线简述

  • 合成目标产物 Tolfenamic Acid 主要起始原料 3-Chloro-2-Methylaniline And 2-Chlorobenzoic Acid
  • (文献来源)合成步骤主要原料 3-Chloro-2-Methylaniline 和 2-Chlorobenzoic Acid
2-(3-Chloro-2-Methylanilino)Benzonitrile置于水,Potassium Hydroxide体系中,用 乙醇 用作溶剂,化学反应 16.0H,以192 Mg的收率获得托灭酸
参考文献:Piii/pv=o催化下硝基芳烃和硼酸的分子间还原c-N交叉偶联
标题:Piii/pv=o催化下硝基芳烃和硼酸的分子间还原c-N交叉偶联
摘要:报道了一种通过分子间 Cn 偶联合成芳基和杂芳基胺的主要基团催化方法.该方法采用基于小环有机磷的催化剂(1,2,2,3,4,4-六甲基膦烷)和末端氢硅烷还原剂(苯基硅烷)来驱动硝基(杂)芳烃与硼酸的还原性分子间偶联.展示了在构建 Csp2-N(来自芳基硼酸)和 Csp3-N 键(来自烷基硼酸)中的应用;该反应在 Csp3-N 键形成方面是立体有择的.该方法构成了一条从现成的构件到有价值的含氮产品的新途径,与现有催化 Cn 偶联方法在范围和化学选择性方面具有互补性.
Doi:10.1021/jacs.8B10769

海关参考信息

专利信息


专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-8546532-B2
优先权日:2008-04-17
标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

专利号:US-7332505-B2
优先权日:1999-02-26
标 题 :Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; LETTS L GORDON; RICHARDSON STEWART K; TAM SANG WILLIAM; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人:BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.
湖北威德利化学科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.widelychemical.com
企业联系电话:13385289472👤
📞湖北威德利化学科技有限公司 ⚠️参考联系方式
联系人:赵方
电话:13385289472
手机:13385289472
传真:027- 59222918
邮箱:z13385289472@163.com
通信地址: 湖北省武汉市硚口区解放大道204号
邮编: 430033
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖北省武汉市硚口区解放大道204号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Ha T, Lou Z, Baek SJ, Lee SH. Tolfenamic acid downregulates β-catenin in colon cancer. Int Immunopharmacol. 2016 Jun;35:287-93. doi: 10.1016/j.intimp.2016.04.008. Epub 2016 Apr 16. doi: 10.1111/jnc.12960. Epub 2014 Oct 18.
3: Subaiea GM, Ahmed AH, Adwan LI, Zawia NH. Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid. J Alzheimers Dis. 2015;43(2):425-33. doi: 10.3233/JAD-132726. doi: 10.1007/s10815-014-0378-x. Epub 2015 Jan 6.
5: Tarushi A, Perontsis S, Hatzidimitriou AG, Papadopoulos AN, Kessissoglou DP, Psomas G. Copper(II) complexes with the non-steroidal anti-inflammatory drug tolfenamic acid: Structure and biological features. J Inorg Biochem. 2015 Aug;149:68-79. doi: 10.1016/j.jinorgbio.2015.02.019. Epub 2015 Mar 6. doi: 10.1016/j.neuropharm.2014.01.009. Epub 2014 Jan 21. doi: 10.1016/j.ijdevneu.2015.07.012. Epub 2015 Aug 10. doi: 10.1158/1940-6207.CAPR-13-0220. Epub 2013 Oct 8.

合成参考文献


参考文献:10.1124/jpet.111.183020
摘要:Chi Y, Li K, Yan Q, Koizumi S, Shi L, Takahashi S, Zhu Y, Matsue H, Takeda M, Kitamura M, Yao J. Nonsteroidal Anti-Inflammatory Drug Flufenamic Acid Is a Potent Activator of AMP-Activated Protein Kinase. The Journal of Pharmacology and Experimental Therapeutics. 2011 Oct;339(1):257–66. doi: 10.1124/jpet.111.183020.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知